Hypotensive and antiischemic efficiency of estulik in course treatment of myocardial infarction complicated by essential hypertension

Aim. To assess hypotensive and antiischemic activity of estulik (Sandos, Sw itzerland) in patients with myocardial infarction (MI) complicated by essen tial hypertension (EH). Materials and methods. 23 MI patients with moderate EN (diastolic blood pre ssure up to 110 mm Hg) and 25 patients with manifest EH (diastolic blood pr essure 115-120 mm Hg) of group 1 and 2, respectively, have, received single doses and a 10-day course of estulik in a dose 0.5-1.0 mg/day. Nemodynamic and antiischemic activities were evaluated at echocardiography, coupled ve loergometry, Holter monitoring, myocardial scintigraphy, polarography. In 3 1% of the patients selective coronarography was made. Results. Clinical condition and hemodynamics of group 1 patients have impro ved by 30-40%, microcirculation has improved by 25-35%. In group 2 patients the drug was found ineffective. Conclusion. Estulik is a drug of choice in moderate EH with manifest angina pectoris.